Rilpivirine: A step forward in tailored HIV treatment

The Lancet

Volumn 378, Issue 9787, 2011, Pages 201-203

  Schrijvers, Rik ^a   Desimmie, Belete Ayele ^a   Debyser, Zeger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DELAVIRDINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RILPIVIRINE; TENOFOVIR;

DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; VIRUS LOAD;

EID: 79960346744     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60992-6     Document Type: Note

References (16)

1. J-M Molina, P Cahn, B Grinsztejn on behalf of the ECHO study group Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial Lancet 378 2011 238 246
2. CJ Cohen, J Andrade-Villanueva, B Clotet on behalf of the THRIVE study group Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial Lancet 378 2011 229 237
3. G Hutter, D Nowak, M Mossner et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation N Engl J Med 360 2009 692 698
4. The Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies Lancet 372 2008 293 299
5. Z Debyser, R Pauwels, K Andries et al. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives Proc Natl Acad Sci USA 88 1991 1451 1455 (Pubitemid 21916242)
6. JV Madruga, P Cahn, B Grinsztejn on behalf of the DUET-1 study group Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 29 38 (Pubitemid 47017466)
7. A Lazzarin, T Campbell, B Clotet on behalf of the DUET-2 study group Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 39 48 (Pubitemid 47017467)
8. F Maggiolo Efavirenz: a decade of clinical experience in the treatment of HIV J Antimicrob Chemother 64 2009 910 928
9. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Jan 10, 2011 (accessed June 22, 2011).
10. L Bacheler, S Jeffrey, G Hanna et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy J Virol 75 2001 4999 5008 (Pubitemid 32448520)
11. AL Pozniak, J Morales-Ramirez, E Katabira et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial AIDS 24 2010 55 65
12. Center for Drug Evaluation and Research (CDER) Food and Drug Administration US Department of Health and Human Services Guidance for industry. Antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf October, 2002 (accessed June 22, 2011).
13. US Food and Drug Administration Approval of Edurant (rilpivirine) a new NNRTI for the treatment of HIV in treatment naive patients http://www.fda.gov/ ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm256151.htm May 20, 2011 (accessed June 22, 2011).
14. C Cohen, JM Molina, P Cahn et al. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients. XVIII International AIDS Conference; Vienna, Austria; July 18-23, 2010: THLBB206 (abstr) http://pag.aids2010.org/Abstracts.aspx?AID=17525 (accessed June 22, 2011).
15. L Rimsky, J Eron, B Clotet et al. Characterization of the resistance profile of TMC278: 48-week analysis of the phase III studies ECHO and THRIVE. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, USA; Sept 12-15, 2010: H-1810 (abstr) http://natap.org/2010/ICAAC/ICAAC-13.htm (accessed June 22, 2011).
16. L Rimsky, J Vingerhoets, V Van Eygen et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients failing rilpivirine (RPV, TMC278) in the phase III studies ECHO and THRIVE: 48 week analysis. 20th International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; Los Cabos, Mexico; June 7-11, 2011: abstract 9 (abstr) http://www.informedhorizons.com/resistance2011/pdf/Rimsky.pdf (accessed June 22, 2011).